Cancer Stem Cells Market Size, Trends, Growth and Competitive Analysis 2022-2032

Cancer Stem Cells Market Size- By Cancer, By Mode Of Action, By Transplantation, By Application, By End User- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032

Cancer Stem Cells Market Size- By Cancer, By Mode Of Action, By Transplantation, By Application, By End User- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032

Published: Dec 2022 Report ID: HLCA2220 Pages: 1 - 226 Formats*:     
Category : Healthcare
Global Cancer Stem Cells Market Overview:

According to SPER Market Research, the Global Cancer Stem Cells Market is estimated to reach USD 2.68 billion by 2032 with a CAGR of 10.29%. 

The tumour’s other cell types are produced by the cancer cell, which has the capacity to divide and grow continuously. Cancer stem cells are believed to oversee tumour development, metastasis, and recurrence. These are the rare forms of godlike cells called cancer stem cells are found in tumours and give rise to a wide range of cell types that make up the tumour. These cells have been identified in several human tumours and may serve as targets for cancer therapy. Most anti-cancer medications function by inducing the death of cancer cells. Even though these treatments seem to be working, some individuals nonetheless have a disease recurrence. The primary driver fuelling the expansion of the cancer stem cell market is the rising incidence of cancer in the world.



Impact of COVID-19 on the Global Cancer Stem Cells Market  
The cancer stem cell sector has prospered from the COVID-19 epidemic. The advent of genetic engineering, which modifies human DNA, and organoid technology, which creates the three-dimensional structure of the tissue from originating stem cells, are two of the most significant strides in stem cell research during COVID-19. The advent of genetic engineering, which modifies human DNA, and organoid technology, which creates the three-dimensional structure of the tissue from stem cells, have been two of the most important strides in stem cell research during Covid-19. This element had a favourable effect on the world market for cancer stem cells. Additionally, there has been an increase in the use of allogeneic stem cell therapy and hematopoietic cell transplantation (HCT), particularly among cancer patients who have Covid-19 infections.



Scope of the Report:
 Report Metric Details
 Market size available for years 2019-2032
 Base year considered 2021
 Forecast period 2022-2032
 Segments coveredBy Cancer, By Mode Of Action, By Transplantation, By Application, By End User
 Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa
 Companies CoveredAbbVie Inc., Advanced Cell Diagnostics Inc., Bionomics, BioNTech, BioTime Inc., Caladrius Biosciences Inc., Celgene Corp., ExCellThera, Gamida Cell, Irvine Scientific, Lonza, MacroGenics, Inc., Menarini Group, Merck KGaA, Mereo BioPharma, Miltenyi,  Biotec, PromoCell GmbH, Propanc Biopharma, Silicon Biosystems, Sino Biological Inc., Thermo Fisher Scientific Inc., ViaCyte Inc.
Global Cancer Stem Cells Market  Segmentation:

By Caner: Based on the Caner, Global Cancer Stem Cells Market is segmented as; Acute Leukemia, Aplastic Anemia, Chronic Lymphocytic Leukemia, Osteopetrosis.

By Mode Of Action: Based on the Mode Of Action, Global Cancer Stem Cells Market is segmented as; Targeted Cancerous Stem Cells {By Anti-CSC Therapeutics (Pathway Inhibitors, Surface Marker Based, Immuno-evasion and Targeting Tumour Microenvironment, Nanoparticle-based Therapies), Products (Cell-Culturing, Cell-Separation, Cell-Analysis, Molecular Analysis)}, Stem Cell Based Cancer Therapy (Autologous SC Transplant, Allogeneic SC Transplant).

By Transplantation: Based on the Transplantation, Global Cancer Stem Cells Market is segmented as; Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy.

By Application: Based on the Application, Global Cancer Stem Cells Market is segmented as; Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer.

By End User:
 Based on the End Use, Global Cancer Stem Cells Market is segmented as; Hospitals and surgical laboratories, Cell banks and tissue banks, Pharmaceutical and biomedical companies.

By Region: Due to improvements in healthcare infrastructure and strong reimbursement policies across the region, North America had the substantial share, accounting for more than two-fifths of the worldwide cancer stem cell market. On the other hand, the Asia-Pacific area will have the fastest growth in the following years. This is because the governments of China, Japan, and India are developing regulations for the development of stem cell research facilities and investing in healthcare infrastructure.

1. Introduction
1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation

3. Executive Summary

4. Market Dynamics
4.1. Driver, Restraint, Opportunity, and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges 
4.2. COVID-19 Impacts of the Global Cancer Stem Cells Market 

5. Market variables and outlook
5.1. SWOT analysis 
5.1.1 Strengths 
5.1.2 Weaknesses 
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis 
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape 
5.2.4 Technological landscape 
5.2.5 Environmental landscape 
5.2.6 Legal landscape 
5.3. PORTER’S five forces analysis 
5.3.1 Bargaining power of suppliers 
5.3.2 Bargaining power of Buyers 
5.3.3 Threat of Substitute 
5.3.4 Threat of new entrant 
5.3.5 Competitive rivalry
5.4. Heat map analysis

6. Global Cancer Stem Cells Market, By Cancer, 2019-2032 (USD Million)
6.1. Acute Leukemia
6.2. Aplastic Anemia
6.3. Chronic Lymphocytic Leukemia
6.4. Osteopetrosis

7. Global Cancer Stem Cells Market, By Mode Of Action, 2019-2032 (USD Million)
7.1 Targeted Cancerous Stem Cells
7.1.1 By Anti-CSC Therapeutics
7.1.1.1 Pathway Inhibitors
7.1.1.2 Surface Marker Based
7.1.1.3 Immuno-evasion and Targeting Tumour Microenvironment
7.1.1.4 Nanoparticle-based Therapies
7.1.2 Products
7.1.2.1 Cell-Culturing
7.1.2.2 Cell-Separation
7.1.2.3 Cell-Analysis
7.1.2.4 Molecular Analysis
7.2 Stem Cell Based Cancer Therapy
7.2.1 Autologous SC Transplant
7.2.2 Allogeneic SC Transplant

8. Global Cancer Stem Cells Market, By Transplantation, 2019-2032 (USD Million)
8.1. Allogeneic Stem Cell Therapy
8.2. Autologous Stem Cell Therapy

9. Global Cancer Stem Cells Market, By Application, 2019-2032 (USD Million)
9.1. Blood Cancer
9.2. Breast Cancer
9.3. Cervical Cancer
9.4. Colorectal Cancer
9.5. Lung Cancer
9.6. Prostate Cancer

10. Global Cancer Stem Cells Market, By End Use, 2019-2032 (USD Million)
10.1 Cell Banks and Tissue Banks
10.2 Hospital and Surgical Laboratories
10.3 Pharmaceutical and Biomedical Companies

11. Global Cancer Stem Cells Market, By Region, 2019-2032 (USD Million)
11.1 North America
11.1.1. United States
11.1.2. Canada
11.1.3. Mexico
11.2 Europe
11.2.1. Germany
11.2.2. United Kingdom
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Rest of Europe
11.3 Asia-Pacific
11.3.1. China
11.3.2. Japan
11.3.3. India
11.3.4. Australia
11.3.5. South Korea
11.3.6. Rest of Asia-Pacific
11.4 South America
11.4.1. Brazil
11.4.2. Argentina
11.4.3. Rest of South America
11.5 Middle East & Africa
11.5.1. Kingdom of Saudi Arabia 
11.5.2. United Arab Emirates
11.5.3. Rest of Middle East & Africa

12. Company Profiles
12.1 AbbVie Inc.
12.1.1. Company details 
12.1.2. Financial outlook
12.1.3. Product summary 
12.1.4. Recent developments

12.2 Advanced Cell Diagnostics Inc.
12.2.1. Company details 
12.2.2. Financial outlook
12.2.3. Product summary 
12.2.4. Recent developments

12.3 Bionomics
12.3.1. Company details 
12.3.2. Financial outlook
12.3.3. Product summary 
12.3.4. Recent developments

12.4 BioNTech
12.4.1. Company details 
12.4.2. Financial outlook
12.4.3. Product summary 
12.4.4. Recent developments

12.5 BioTime Inc.
12.5.1. Company details 
12.5.2. Financial outlook
12.5.3. Product summary 
12.5.4. Recent developments

12.6 Caladrius Biosciences Inc.
12.6.1. Company details 
12.6.2. Financial outlook
12.6.3. Product summary 
12.6.4. Recent developments

12.7 Celgene Corp.
12.7.1. Company details 
12.7.2. Financial outlook
12.7.3. Product summary 
12.7.4. Recent developments

12.8 ExCellThera
12.8.1. Company details 
12.8.2. Financial outlook
12.8.3. Product summary 
12.8.4. Recent developments

12.9 Gamida Cell
12.9.1. Company details 
12.9.2. Financial outlook
12.9.3. Product summary 
12.9.4. Recent developments

12.10 Irvine Scientific
12.10.1. Company details 
12.10.2. Financial outlook
12.10.3. Product summary 
12.10.4. Recent developments

12.11 Lonza
12.11.1. Company details 
12.11.2. Financial outlook
12.11.3. Product summary 
12.11.4. Recent developments

12.12 MacroGenics Inc.
12.12.1. Company details 
12.12.2. Financial outlook
12.12.3. Product summary 
12.12.4. Recent developments

12.13 Menarini Group
12.13.1. Company details 
12.13.2. Financial outlook
12.13.3. Product summary 
12.13.4. Recent developments

12.14 Merck KGaA
12.14.1. Company details 
12.14.2. Financial outlook
12.14.3. Product summary 
12.14.4. Recent developments

12.15 Mereo BioPharma
12.15.1. Company details 
12.15.2. Financial outlook
12.15.3. Product summary 
12.15.4. Recent developments

12.16 Miltenyi Biotec
12.16.1. Company details 
12.16.2. Financial outlook
12.16.3. Product summary 
12.16.4. Recent developments

12.17 PromoCell GmbH
12.17.1. Company details 
12.17.2. Financial outlook
12.17.3. Product summary 
12.17.4. Recent developments

12.18 Propanc Biopharma
12.18.1. Company details 
12.18.2. Financial outlook
12.18.3. Product summary 
12.18.4. Recent developments

12.19 Silicon Biosystems
12.19.1. Company details 
12.19.2. Financial outlook
12.19.3. Product summary 
12.19.4. Recent developments

12.20 Sino Biological Inc.
12.20.1. Company details 
12.20.2. Financial outlook
12.20.3. Product summary 
12.20.4. Recent developments

12.21 Thermo Fisher Scientific Inc.
12.21.1. Company details 
12.21.2. Financial outlook
12.21.3. Product summary 
12.21.4. Recent developments

12.22 VIaCyte Inc.
12.22.1. Company details 
12.22.2. Financial outlook
12.22.3. Product summary 
12.22.4. Recent developments

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3


Frequently Asked Questions About This Report
The North America region is anticipated to have the highest market share in the Cancer Stem Cells Market.
The Cancer Stem Cells Market is projected to reach USD 2.68 billion by 2032, growing at a CAGR of 10.29% during the forecast period.
The Cancer Stem Cells Market grew in market size from 2021. The Market is expected to reach USD 2.68 billion by 2032, at a CAGR of 10.29% during the forecast period.
The Cancer Stem Cells Market CAGR of 10.29% during the forecast period.
You can get the sample pages by clicking the link - Click Here
The Cancer Stem Cells Market size is USD 2.68 billion from 2022 to 2032.
The Cancer Stem Cells Market segment is Covered By Cancer, By Mode Of Action, By Transplantation, By Application, By End User.
The key players in the market include Companies Covered AbbVie Inc., Advanced Cell Diagnostics Inc., Bionomics, BioNTech, BioTime Inc., Caladrius Biosciences Inc., Celgene Corp., ExCellThera, Gamida Cell, Irvine Scientific, Lonza, MacroGenics, Inc., Menarini Group, Merck KGaA, Mereo BioPharma, Miltenyi, Biotec, PromoCell GmbH, Propanc Biopharma, Silicon Biosystems, Sino Biological Inc., Thermo Fisher Scientific Inc., ViaCyte Inc.
The growing global cancer incidence is the key force driving the growth of the cancer stem cell market.
Not able to find what you are looking for? Need customization in the existing report?
Click Here
PLACE AN ORDER
  • 15% off
     
    $ 4250
  • 20% off
             
    $ 5650
  • 25% off
         
    $ 7450
Pre-Purchase Inquiry
SEND AN INQUIRY
NEED CUSTOMIZATION?
Request Customization
CALL OR EMAIL US
US:
India:
Email:
100% Secure Payment

SPER American Express
SPER VISA
SPER Master Card
SPER Mestro
SPER Paypal
SPER CCAvenues

Join Our SPER Panel

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB

SPER

Market Research

We are the leading, full-service global market research and consulting company.

Certificates
iso-1 iso-1
Secure Payments
SPER Payment Options
Connect with us